Therapy with omalizumab in patients with severe persistant allergic asthma: A real life data in Turkey;Aǧir allerjik astimli hastalarda anti-IgE (omalizumab) tedavisi: Gerçek yaşam verileri

Tuberkuloz ve Toraks

Volumn 58, Issue 4, 2010, Pages 425-434

  Bavbek, Sevim ^a   Aydin, Ömür ^a   Kepil Özdemir, Seçil ^a   Yilmaz, Insu ^a   Çelik, Gülfem E ^a   Demirel, Yavuz Selim ^a   Mungan, Dilşad ^a   Sin, Betül ^a   Kurşun, Nazmiye ^a   Misirligil, Zeynep ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Allergic asthma; Anti IgE; Asthma; Omalizumab; Severe asthma

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; OMALIZUMAB; STEROID;

ADULT; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; MALE; MITE; TREATMENT DURATION; TURKEY (REPUBLIC); UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN E; TREATMENT OUTCOME; TURKEY;

EID: 78651398065     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Burr ML, Wat D, Evans C, Dunstan FDJ, Doull IJM on behalf of the British Thoracic Society Research Committee. Asthma prevalence in 1973, 1988 and 2003. Thorax 2006; 61: 296-9.
2. Mathur SK, Busse WW. Asthma: diagnosis and management. Med Clin N Am 2006; 90: 39-60.
3. Bavbek S, Misirligil Z; Study Group. A breath for health: an exploratory study in severe asthma patients in Turkey. Allergy 2008; 63: 1218-27.
4. Celik GE, Bavbek S, Paşaoǧlu G, et al. Direct medical cost of asthma in Ankara, Turkey. Respiration 2004; 71: 587-93.
5. Rolinck-Werninghaus C, Wahn U, Hamelmann E. Anti-IgE therapy in allergic asthma. Curr Drug Targets-Inflam-Allergy 2005; 4: 551-64.
6. Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005; 11: 27-34.
7. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-40.
8. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 23; 341:1966-73.
9. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90. (Pubitemid 32735398)
10. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.
11. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunglobulin E antibody (omalizumab). Pediatrics 2001; 108: 36-45.
12. Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-40. (Pubitemid 34150431)
13. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16.
14. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8. (Pubitemid 40293345)
15. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-17. (Pubitemid 38850345)
16. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-tosever) allergic asthma. Allergy 2004; 59: 701-8. (Pubitemid 38850344)
17. Corren J, Casale T, Lanier BQ. Omalizumab is well tolerated in adolescent/adult patients (> 12 years) with moderate to severe asthma. J Allergy Clin Immunol 2005; 115: S75.
18. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102: 71-6.
19. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103: 1725-31.
20. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-42
21. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian reallife experience of omalizumab. Respir Med 2010; 104: 1410-6.
22. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16.
23. Busse WW, Massanari M, Kianifard F, Geba GP. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23: 2379-86.
24. Niven R. A UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax 2007; 62 (Suppl 3): A98, P91.
25. Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010; 104: 1381-5.